When recombinant human IL-21 was used in combination with the monoclonal antibody cetuximab, which targets the epidermal growth factor receptor, enhanced anti-tumor activity was observed, with serum sCD25 levels increasing in a dose-dependent manner, and 60% of patients achieving stable disease (210). The gene discussed is IL21; the disease is neoplasm.